NeoGenomics, Inc. (NASDAQ:NEO) Q1 2026 Earnings Call Transcript
Operator: Good afternoon, and welcome to the NeoGenomics First Quarter 2026 Financial Results Call. Please be advised that today's conference is being recorded.
Neogenomics Inc (NEO)
Market is closed
Sector: Services-Testing Laboratories
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | 27,000 | $23,925 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.62 | 20,000 | $112,322.00 | 188,332 | 2025-08-06 | Filing | |
| $5.58 | 17,900 | $99,953.60 | 38,066 | 2025-08-06 | Filing | |
| $7.60 | 5,000 | $38,000.00 | 5,000 | 2025-05-27 | Filing | |
| $8.58 | 5,700 | $48,894.60 | 108,280 | 2025-05-12 | Filing | |
| $8.14 | 7,000 | $56,974.40 | 7,000 | 2025-05-09 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $12.50 | 22,128 | $276,681.87 | 121,631 | 2026-01-20 | Filing | |
| $12.00 | 20,916 | $250,992.00 | 31,083 | 2025-11-25 | Filing | |
| $15.36 | 5,175 | $79,475.06 | 37,129 | 2024-11-15 | Filing | |
| $16.05 | 1,040 | $16,695.43 | 43,813 | 2024-08-15 | Filing | |
| $15.74 | 1,049 | $16,511.26 | 44,867 | 2024-05-15 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 7,622,187 | $56,556,628 | 0% | |
| 2. | 5,655,823 | $41,966,207 | 0% | |
| 3. | 2,674,335 | $19,841,941 | 0% | |
| 4. | 2,026,893 | $15,039,546 | 0.02% | |
| 5. | 13,479,000 | $12,340,444 | 0.34% |
News See All
11 Most Buzzing Stocks to Buy with the Highest Upside Potential
On March 4, Henry McVey, Head of Global Macro & Asset Allocation at KKR and CIO of the firm's balance sheet, appeared on CNBC's 'Closing Bell Overtime' to talk about the geopolitical worries vexing the...
NeoGenomics, Inc. (NASDAQ:NEO) Q4 2025 Earnings Call Transcript
Operator: Good morning, and welcome to the NeoGenomics, Inc. Fourth Quarter and Full Year 2025 Financial Results Call. Please be advised that today's conference is being recorded.
NeoGenomics, Inc. (NASDAQ:NEO) Q3 2025 Earnings Call Transcript
Operator: Good morning, everyone, and welcome to the NeoGenomics Third Quarter 2025 Financial Results Call. [Operator Instructions] Please note, this conference is being recorded.
Here’s Alger Weatherbie Specialized Growth Fund’s Comment on NeoGenomics (NEO)
Fred Alger Management, an investment management company, released its “Alger Weatherbie Specialized Growth Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Brown Advisory Small-Cap Growth Strategy Sold Neogenomics (NEO) Following the News of CEO Departure
Brown Advisory, an investment management company, released its "Brown Advisory Small-Cap Growth Strategy" second-quarter 2025 investor letter.
NeoGenomics (NEO) Targets Opportunity at $5 billion Liquid Biopsy Market
NeoGenomics, Inc. (NASDAQ:NEO) is one of the top 10 medical AI companies to buy according to analysts.
Top 10 Medical AI Companies to Buy According to Analysts
Artificial intelligence is transforming medical sciences in ways not seen before.
NeoGenomics, Inc. (NASDAQ:NEO) Q2 2025 Earnings Call Transcript
Operator: Good morning, and welcome to the NeoGenomics Second Quarter 2025 Financial Results Call. [Operator Instructions] Please be advised that today's conference is being recorded.
Here’s Why NeoGenomics (NEO) Sold Off in Q1
Janus Henderson Investors, an investment management company, released its “Janus Henderson Venture Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here.
Hedge Fund Resource Center